Business Wire

CHRYSO

Share
CHRYSO and SOLIDIA Partner to Deploy Ultra-low CO2 Concrete

CHRYSO, a world leader in construction chemicals, today announces its partnership with Solidia Technologies, a start-up inventor of revolutionary technology for green cement and concrete. The two companies will collaborate to improve the sustainability performance and material properties of Solidia® ultra-low CO2 concrete through their combined chemical expertise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200909005655/en/

The partnership is underpinned by a long-term commitment from both companies to making sustainable solutions accessible to cement and concrete producers worldwide.
Solidia® sustainable technology is already available in the precast market and used for non-reinforced concrete elements. Solidia’s unique technologies are based on a revolutionary cement chemistry that can be produced at lower energies, significantly lowering carbon emissions, and that does not hydrate but carbonates by injection of CO2 into fresh concrete. Combined, Solidia’s processes lower the carbon footprint of concrete by up to 70%, while reducing water and energy consumption. They also improve the performance and durability of concrete, which are further enhanced with new, sophisticated admixture solution.
CHRYSO draws on a solid knowledge of sustainable building materials. For more than 10 years, the company has been developing admixture solutions that allow the intensive use of alternative binders without compromising material performance.

“The development of innovative admixture solutions adapted to Solidia’s new binder, boosting the final properties of concrete, is one of our R&D works in progress. This will enable higher strengths, an improved finish of the fresh concrete, and the optimization of the curing process. Together with Solidia, we will scale the use of low CO2 concrete, helping manufacturers produce high quality precast elements,” declared Jean Mascaro, Concrete BU director of CHRYSO.

Tom Schuler, president and CEO of Solidia Technologies , said: “Incorporating CHRYSO® ’s exclusive water-reducing admixtures adapted to the specific chemistry of Solidia Concrete™, will further reduce water consumption in the curing process.”
A key objective for the start-up is to improve cement and concrete production and performance while enhancing its environmental impact. Tom Schuler added: “By cutting energy consumption during the curing process, CHRYSO will help us achieve our ambitions and reach higher levels of performance.”

This partnership paves the way for upcoming advances in CO 2 footprint reduction and new developments in sustainable chemistry. The deployment of new ultra-low C0 2 concrete will accelerate the decarbonization of the construction industry.

About the CHRYSO Group
Aimed at cement manufacturers, ready-mix concrete and precast industrials, and construction companies, CHRYSO's offer includes cement additives, concrete admixtures and Solutions for Construction Systems (waterproofing solutions, mortars, etc.). CHRYSO® solutions have won renown on the most prestigious construction sites throughout the world thanks to the group's extensive network, which includes 22 foreign subsidiaries and covers more than 100 countries through its wide network of distributors, licensees and agents. The CHRYSO group employs over 1,300 staff worldwide. Innovation, customer service, expertise and technical know-how are the CHRYSO Group's cornerstones. More info about CHRYSO: www.chryso.com

About Solidia Technolgies
Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to manufacture superior, sustainable building materials. Each year, Solidia can eliminate at least 1.5 Gt of CO₂, save 3 trillion liters of fresh water, reduce cement industry energy consumption by 67 Mt of coal, and eliminate 100 Mt of concrete waste landfill. Produced using the same raw materials and existing equipment, Solidia products are higher performing and cost less to produce than traditional concrete, and cure in less than 24 hours. Solidia offers a rapid, globally scalable response to one of the greatest threats to our planet.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye